Author:
Fukata Norimasa, ,Okazaki Kazuichi,Omiya Mika,Matsushita Mitsunobu,Watanabe Mamoru
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Jones JL, Loftus EV Jr. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis. 2007;13:1299–307.
2. Ueno F, Matsui T, Matsumoto T, et al. Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan. J Gastroenterol. 2013;48:31–72.
3. Hamilton MJ, Snapper SB, Blumberg RS. Update on biologic pathways in inflammatory bowel disease and their therapeutic relevance. J Gastroenterol. 2012;47:1–8.
4. Hoshida Y, Xu J-X, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinic-pathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007;34:322–31.
5. Kondo S, Tanimoto K, Yamada K, et al. Mature T/NK-cell lymphoproliferative disease and Epstein-Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate. Virchows Arch. 2013;462:399–407.
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献